Search hospitals > Illinois > Chicago
University of Illinois Cancer Center
Claim this profileChicago, Illinois 60612
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Leukemia
Conducts research for Lymphoma
Conducts research for Cancer
118 reported clinical trials
16 medical researchers
Summary
University of Illinois Cancer Center is a medical facility located in Chicago, Illinois. This center is recognized for care of Breast Cancer, Lung Cancer, Leukemia, Lymphoma, Cancer and other specialties. University of Illinois Cancer Center is involved with conducting 118 clinical trials across 135 conditions. There are 16 research doctors associated with this hospital, such as Lawrence E. Feldman, Shikha Jain, Paul Rubinstein, MD, and Oana Danciu.Area of expertise
1Breast Cancer
Global LeaderStage IV
Stage III
HER2 negative
2Lung Cancer
Global LeaderStage IV
Stage III
chemotherapy
Top PIs
Lawrence E. FeldmanUniversity of Illinois5 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
29 reported clinical trials
42 drugs studied
Shikha JainUniversity of Illinois4 years of reported clinical research
Studies Adenocarcinoma
Studies Colorectal Cancer
16 reported clinical trials
35 drugs studied
Paul Rubinstein, MDUniversity of Illinois1 year of reported clinical research
Expert in Lymphoma
Studies Diffuse Large B-Cell Lymphoma
14 reported clinical trials
35 drugs studied
Oana DanciuUniversity of Illinois9 years of reported clinical research
Studies Breast Cancer
Studies Cancer
12 reported clinical trials
47 drugs studied
Clinical Trials running at University of Illinois Cancer Center
Breast Cancer
Cancer
Lung Cancer
Small Cell Lung Cancer
Multiple Myeloma
Lymphoma
Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma
Recurrence
Ovarian Cancer
Ribociclib + Endocrine Therapy
for Breast Cancer Recurrence
This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.
Recruiting1 award Phase 212 criteria
Low Dose Azacitidine
for Early Stage Breast Cancer
This trial is testing if low dose azacitidine can help the immune system fight high-risk early stage breast cancer. The treatment aims to increase immune cells that attack cancer cells. It targets patients whose cancer is more likely to return or spread.
Recruiting1 award Phase 210 criteria
Alpelisib + Endocrine Therapy
for Breast Cancer
Patients who have histologically confirmed metastatic or unresectable (not amenable to curative therapy) breast cancer may be screened for eligibility. All patients must have HER2 negative breast cancer with the identified PIK3CA mutation and received at least one line of endocrine therapy. The study will consist of a screening phase, a treatment phase, and a post-treatment phase which includes safety, efficacy, and follow-up. The treatment phase will include taking alpelisib daily in combination with continued use of either Fulvestrant or Aromatase Inhibitor per standard of care until disease progression or unacceptable toxicity.
Recruiting1 award Phase 218 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at University of Illinois Cancer Center?
University of Illinois Cancer Center is a medical facility located in Chicago, Illinois. This center is recognized for care of Breast Cancer, Lung Cancer, Leukemia, Lymphoma, Cancer and other specialties. University of Illinois Cancer Center is involved with conducting 118 clinical trials across 135 conditions. There are 16 research doctors associated with this hospital, such as Lawrence E. Feldman, Shikha Jain, Paul Rubinstein, MD, and Oana Danciu.